Institute of Health Information and Statistics of the Czech Republic
University of Catania
FINNADVANCE (FIN)
PDC Biotech GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age: ≥ 18
PFS≤2
Patients willing to sign an informed consent;
Confirmed (cytologically or histologically) cutaneous melanoma diagnosis
Confirmed BRAF p. V600E tumor status
Eligible for BRAFi/MEKi treatment or Immune checkpoint blockade in either the adjuvant or advanced settings (the latter typically stages III/IV, high risk).
You may not be if
Life expectancy \<8 weeks
Other clinical conditions preventing blood drawing compliance, as per physician's choice.
Clareo Health | Versatile Ampification Single-Molecule Detection in Liquid Biopsy
